chronic atrophic gastritis
Conditions
Interventions
Treatment of Weierkang:oral administration of Weierkang for 3 months
Treatment of teprenone and folic acid:oral administration of teprenone and folic acid for 3 months
Sponsors
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Referring to consensus on chronic gastritis in China(Shanghai, 2012), diagnostic criteria are listed as follows: 1. Outpatients of CAG from October,2016 to September, 2017 at Sir Run Run Shaw Hospital; 2. Aged between 20 and 70 years old.
Exclusion criteria
Exclusion criteria: 1. Combined with malignant tumor,espencially esophageal cancer and gastric cancer; ulcer, barretts esophagus or other upper GI diseases; 2. Acid inhibitors (H2 antagonists or proton pump inhibitors)promote power medicine (mosapride or domperidone, etc.) or gastric mucosa protectant for pury (teprenone, sucralfate, gefarnate, glutamine, rebamipide, bismuth, etc.) were taken two weeks before this trial; 3. Serious comorbidities of heart, lung, liver, kidney or blood system; 4. Female patients preparing for a baby, pregnant or lactating; 5. Dropping out of this trials before the end of treatment, or can't cooperate with researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total effective rate; | — |
Countries
China
Contacts
Public ContactChen Shujie
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Outcome results
None listed